Genmab, BioNTech Expand Research Partnership for Cancer Treatments
05 Agosto 2022 - 8:30AM
Dow Jones News
By Chris Wack
Genmab AS and BioNTech SE said they are expanding their global
strategic collaboration to develop and commercialize novel
immunotherapies for the treatment of cancer patients.
Under the expansion, Genmab and BioNTech will jointly work to
research, develop and commercialize novel monospecific antibody
candidates for various cancer indications.
The companies have been working on the joint development of
bispecific cancer antibodies aimed at improving immunotherapy
options for cancer patients since 2015.
Under the expanded collaboration, the companies will jointly
develop and commercialize, subject to regulatory approval,
monospecific antibodies using Genmab's proprietary HexaBody
technology platform. The first monospecific antibody candidate,
GEN1053/BNT313, is expected to enter clinical trials by the end of
2022.
Under the terms of the agreement, the companies will equally
share the development costs and potential future profit deriving
from GEN1053/BNT313.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
August 05, 2022 07:15 ET (11:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
